News

This milestone signals the initiation by Merck of a Phase I clinical study of an investigational compound using the MicroDose dry powder inhaler (DPI) technology. As previously announced,

In each of the two placebo-controlled efficacy and safety trials, patients treated with tranexamic acid MR experienced a significant reduction in mean monthly menstrual blood loss compared with

According to Capricorn, korkoat beads accommodate high drug loads; modified drug release can be achieved by incorporating release-modifying agents inside the bead, in the coating, or in both.

This multi-site trial enrolled patients with cystoid macular edema associated with retinal vein occlusion and post operative cataract surgery. IBI-20089 is a drug product based on Icon Bioscience’s

The PhotoMedex (PHMD) division provides mobile laser services in 11 Northeast, Mid-Atlantic and Southeast states, serving 18 individual local markets expanding PRI’s geographic coverage to a total of

Dr Gussak joins NewCardio from Boehringer Ingelheim Pharmaceuticals, where he held a senior executive role for the past year. Dr Gussak received his MD from Tartu University School

As part of the three-year agreement, the companies will employ the same underlying technology used in their previously announced joint project, a diagnostic for the differential diagnosis of

Sanofi-Aventis will pay Regeneron a minimum of $4.3 million annually for five years for knock-out and transgenic models of gene function for target genes identified by Sanofi-Aventis. Sanofi-Aventis

The purpose of the Phase I/II clinical trial is to evaluate the safety and tolerance of Triolex when administered orally for 28 days at three different dose levels.